Blocs, shocks and two smoking ballots: 2024 and the world’s mega election year

Raising the Bar: How the 2024 Access to Medicine Index Shapes the Pharmaceutical Industry’s ESG Agenda

The Good, the Bad, and the Ugly: Australia’s HTA Review Final Report

Is the new price right?: HTA takes a back seat to broader price negotiations

Could Human HTA Committees be Replaced with AI Systems?

WFH ... WTF ... ????: Working-from-home, employer reaction and pandemic-inspired industrial changes

It’s not easy being green: environmental sustainability in health systems, health industries and health economics

Short Memories: Has Health Fallen Off the Global Agenda? What Does it Mean for Pharma?

Ghosts in the Machine: the search for productivity measures in health technology assessment

Bungled Brexit, Bad Boris and a Broken NHS: the issues stalking Britain’s national election

Changing Ourselves to Change the World: Engaging in India’s Pharma Development Strategy

Here we are now, entertain us: the Gen X factor in intergenerational politics

More ‘us’ and less ‘them’ thinking: a plea for 2024

Christmas Santa or Christmas Scrooge?: England's new medicines pricing regime sends mixed messages

Déjà vu all over again?: Australia’s industrial policy debate

Time to Build More Windmills: Reflections from the ChinaBio Innovation & Investment Conference 2023

Universal Health Coverage at the Half-Way Point: Political Disappointment & Business Opportunity

Land of the Long Wait Crowd: problems in New Zealand's medicine funding system

Have health and the PBS come of age as the Intergenerational Report turns 21?

The 2023 WHO Essential Medicines List & The Importance of Industry Engagement